AI Analysis
AI-generated analysis. Always verify with the original filing.
Sanofi announces four key regulatory milestones: Dupixent approval in Japan for bullous pemphigoid, CHMP positive opinion for Sarclisa subcutaneous in multiple myeloma, positive amlitelimab phase 3 data in atopic dermatitis, and Rezurock approval in EU for chronic GVHD.
Key Takeaways
1Dupixent (dupilumab) approved in Japan as first targeted therapy for adults with moderate-to-severe bullous pemphigoid, based on LIBERTY-BP-ADEPT study showing 18% vs 4% sustained remission at Week 36.
2Sarclisa subcutaneous formulation via on-body injector recommended for EU approval by CHMP across all multiple myeloma indications, demonstrating non-inferiority to IV in IRAKLIA phase 3 study.
3Amlitelimab phase 3 studies (COAST 1, COAST 2, SHORE) showed significant skin clearance improvements at Week 24 with Q4W or Q12W dosing vs placebo in moderate-to-severe atopic dermatitis.
4Rezurock (belumosudil) received EU conditional approval for chronic GVHD in adults and children ≥12 years (≥40kg) after limited treatment options, based on ROCKstar phase 2 study with 74% ORR.